In contrast, Annexin A5 (ANXA5) presents a counter-regulatory mechanism by interacting with PKM2 to inhibit its phosphorylation, thus promoting the formation of metabolically active tetramers and modulating macrophage activation in NASH (166). Here, ANXA5 is linked to metabolic dysfunction-associated steatohepatitis.